Physician profile
Loretta J Pace
NPI 1346005139
$1,004.40
in general payments reported to CMS, 2019-2025
15 companies · $296 in 2025
The $296 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $708 · 2025: $296.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,004.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,004.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $244.63 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $140.28 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $103.48 | 2024-2025 | Airsupra, Farxiga |
| Pfizer INC. | $85.95 | 2024-2025 | |
| Novo Nordisk INC | $67.10 | 2024-2025 | Ozempic, Rybelsus |
| Exact Sciences Corporation | $65.70 | 2024-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $57.25 | 2024-2025 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $51.94 | 2024-2025 | Xifaxan |
| Mylan Specialty L.P. | $41.17 | 2024 | Yupelri |
| Axsome Therapeutics, INC. | $38.24 | 2024 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $27.30 | 2024 | Eliquis |
| Abbvie INC. | $25.68 | 2024 | |
| Glaxosmithkline, LLC. | $24.30 | 2025 | Shingrix, Arexvy |
| Otsuka America Pharmaceutical, INC. | $17.69 | 2024 | Rexulti |
| Viatris Specialty LLC | $13.69 | 2025 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Loretta Pace listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.